VANCOUVER, British Columbia, Oct. 04, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”) , a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and nutraceutical products, is pleased to announce that the Company has officially initiated the approval process to begin exporting its flagship product, Isoderm to Chile.
Marcos Agramont, CEO of Isodiol, stated, “Earlier this year, Chile became the first country in Latin America to allow the sale of cannabis-based medicines in pharmacies. This gives the Company a unique advantage considering our distribution partner, FarmaUSA, has existing distribution channels that we will be able to immediately utilize. We are thrilled by the possibility of expanding Isodiol’s Latin American market initiative to provide Chilean patients with high quality CBD products. As the global market evolves, Isodiol has every intention to be at the forefront of product development and innovation.”
Chile legalized the use of medicinal marijuana in 2015 and is among a number of Latin American countries gradually loosening laws prohibiting the cultivation, distribution, and consumption of cannabis. Isodiol is one of the first companies to register a CBD product with the Chilean Health Department.
Isoderm Direct Effects Technology™ CBD Cream is the Company’s innovative new product that is applied directly to the back of the neck at the hairline for delivery of cannabinoids using direct nerve connections of skin to central nervous system (CNS), without blood flow requirements and restrictions of blood-brain barrier. The proprietary formulation delivers fast relief from neurologic, psychiatric and pain conditions, without concerns of systemic side effects and drug interactions commonly encountered with systemic neuro-active compounds.
The Company anticipates the introduction of additional products into the Chilean market including new non-cannabis derived CBD products.
For more information on Isodiol, please visit www.isodiol.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical and nutraceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Join Us On Facebook : https://www.facebook.com/isodiol/ Twitter: @isodiol
ON BEHALF OF THE BOARD Marcos Agramont, CEO & Director
INVESTOR RELATIONS: Ir@isodiol.com www.isodiol.com
MEDIA CONTACT: Carrie Booze North 6th Agency 212-334-9753 ext.142 Isodiol@n6a.com
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.
